Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
SLE
Rheumatology
| Question | Answer |
|---|---|
| SLE prevalence | 90% of all pts = women; occur in all sexes, age / ethnic; US: 15-50/100,000 (highest: AA females) |
| SLE epi | urban > rural; tripled in 40 yrs; M: less photosensitivity, more serositis; Elderly: milder disease |
| SLE age of onset | 20% < 16; 65% btw 16-55; 15% >55 |
| SLE pathophysiology | >100 genes; many environ factors; UV light (triggers photosensitivity rashes); drugs (sulfonamides); SMK; infxn (EBV, ?parvo B-19); hormones |
| SLE pathogenesis: 5 stages | 1: Susceptibility 2: innate/adaptive immune responses 3: AutoAbs, immune complexes (complexes trigger complement) in visceral tissue capillaries 4: inflammation 5: tissue damage |
| SLE genl clinical findings | systemic, cardiopulmonary; GI, Neuropsychiatric; derm |
| SLE: Cardiopulmonary findings: | pleuritis/pl effusion / serositis; pericarditis / effusion; interstitial pneumonia; pulmo HTN |
| SLE: GI findings: | hepatitis; HSM; esophageal dysmotility; pancreatitis |
| SLE: Neuropsychiatric findings: | cognitive impairment; HA |
| SLE: Derm findings: | photosensitivity; malar rash; discoid lesions; nonspecific maculopapular lesions; ulcers of oral, genital, nasal mucosa; alopecia |
| most serious manifestation of SLE = | renal disease; may be asx early; leading cause of mortality |
| SLE classic renal manifestation = | nephritis (histo classed as I-VI); 50% pts also develop nephrotic syn; untx’d nephritis can lead to ESRD in 2 years |
| SLE classic MS presentation | polyarthritis similar in distribution to RA; non-erosive, non-deforming; pt sx may be disproportionate to physical findings; also: ischemic necrosis; myalgias |
| most common SLE clin findings | systemic; arthralgias/myalgias; photosensitivity; malar rash; cognitive impairment |
| Most common Ab’s assoc with SLE | ANA (best screening test); dsDNA (hi titer diagnostic); anti-Smith (specific not sensitive); anti-RNP (not spec for SLE); Ro, La. False pos VDRL |
| Drug-induced lupus = | Syndrome of pos ANA assoc w/ constellation of sx (malaise, fever, arthritis +/-myalgias, rash, serositis); autoimmune-mediated response; W > AA; renal/ CNS sx rare; MANY causative drugs |
| DILE: dx criteria | 1 or more SLE clinical sx; pos ANA; no hx SLE before suspected drug; drug taken 3 wks-2 yrs prior to sx; Drug withdrawal led to sx improvement |
| acute cutaneous lupus = | localized or generalized; usu do have systemic dz (3 forms: classic malar rash; genl erythema; bullous dz) |
| subacute cutaneous lupus = | annular or papulosquamous (AKA psoriaform: sl raised) |
| chronic cutaneous lupus = | discoid lupus; host of nonspecific LE lesions |
| Prevalence of systemic lupus in cutaneous lupus pts | Acute: 100% have systemic lupus; Subacute: 50%; Chronic cutaneous: 25% |
| Discoid lesions: incidence | develop in 25% of SLE pts; also may occur in absence of any other clinical manifestations |
| DLE pt: risk of developing SLE | DLE pt 5-10% risk of developing SLE which tends to be mild |
| Patients with DLE: number of discoid lesions: | Increased number of lesions correlates with increased risk (of developing SLE) |
| DLE common sites | face, neck, scalp |
| SLE tx: | Systemic glucocorticoids (mainstay of life-threatening manifestations); major organ involvement guides tx options |
| SLE: tx: mild-moderate MS sx | NSAIDs |
| SLE: tx: cutaneous & mild-moderate MS sx | Anti-malarials (mostly hydroxychloroquinine) |
| SLE: tx: mod-severe dz (major organ involvemt) or severe/ refractory dz w/o organ involvemt | Azathioprine, methotrexate, cyclophosphamide, (CellCept) |
| Fibromyalgia & SLE | 50% of patients with lupus have fibromyalgia |
| Livedo reticularis seen in: | SLE; APS |
| MCTD Sx: | severe Raynaud; swollen, puffy hands, arthritis; nail capillary changes; may have any/ many sx of SLE & scleroderma |
| MCTD Testing: | pos anti-RNP Ab |
| MCTD Tx | like SLE & scleroderma, depending on sx |
| UCTD | Lupus-Light; a few sx like autoimmune, but not enough to fulfill the dx; usu pts won’t progress to lupus |
| SLE Dx criteria | must meet 4 of 11 criteria: malar, discoid, photosensitivity, oral ulcers, arthritis, serositis (ht,lung, peritoneal), renal, ANA, hemo, imm dz (anti-DNA, anti-Sm), neuro |
| Drugs that precipitate SLE flare | procainamide, hydralazine, INH, methyldopa, quinidine, chlorpromazine, cimetidine, HCTZ; penicillin; sulfonamides; terbinafine |
| SLE pathophysiology | >100 genes; many environ factors; UV light; sulfonamides; SMK; EBV, ?parvo B19); hormones |
| SLE: Cardiopulmonary findings: | pleuritis/pl effusion / serositis; pericarditis / effusion; interstitial pneumonia; pulmo HTN |
| SLE: GI findings: | hepatitis; HSM; esophageal dysmotility; pancreatitis |
| SLE: Derm findings: | photosensitivity; malar rash; discoid lesions; nonspecific maculopapular lesions; ulcers of oral, genital, nasal mucosa; alopecia; occur in almost all SLE pts |
| Mixed Connective Tissue Dz defn | overlap syndrome of lupus & scleroderma |
| Mixed Connective Tissue Dz Sx: | severe Raynaud; swollen, puffy hands, arthritis; nail capillary changes; may have any/ many sx of SLE & scleroderma |
| Collagen vascular dz includes: | RA, SLE, Scleroderma, Dermatomyositis, Polyarteritis nodosa |
| Female with arthralgias, malar rash, +ANA, + anti-double stranded DNA Abs, +anti-phospholipid Abs = | SLE |
| Dusky red, well localized single or multiple papules or plaques usually of face | Discoid lupus |
| SLE tx: | Exercise & sun protection; Systemic glucocorticoids (mainstay of life-threatening sxs); major organ involvement guides tx options |
| SLE: tx: mild-moderate MS sx | NSAIDs |
| SLE: tx: cutaneous & mild-moderate MS sx | Anti-malarials (mostly hydroxychloroquinine), c'steroids |
| SLE: tx: mod-severe dz (major organ involvemt) or severe/ refractory dz w/o organ involvemt | Azathioprine, methotrexate, cyclophosphamide, mycophenolate (CellCept) |
Created by:
Abarnard
Popular Medical sets